ClinPharm ClinPharm ClinPharm DOM Schulich UWO
Welcome!

"Clinical Pharmacology is a discipline dedicated to the bench-to-bedside study of drug action through an in-depth knowledge of human pharmacology and therapeutics"

Welcome to the Division of Clinical Pharmacology. We are a Division within in the Department of Medicine at the University of Western Ontario Schulich School of Medicine & Dentistry. Our faculty is dedicated to advancing our knowledge of determinants of variation in drug disposition, adverse drug reactions, and to uncover novel mechanisms of drug action. We believe in a multidisciplinary approach to studying drug responsiveness in health and disease.

Expertise in our division encompass areas of Personalized Medicine, Drug Metabolizing Enzymes & Transporters, Pharmacokinetics, Drug Interactions & Polypharmacy, Drug Safety, Vascular Response & Stroke, and Pharmacoepidemiology of relevance to both adult and pediatric patient populations.

In addition to research, we offer an outstanding subspecialty residency training program in Clinical Pharmacology. Clinical Pharmacology is a Royal College of Physicians and Surgeons of Canada recognized subspecialty. We are one of the few sites in Canada offering a Clinical Pharmacology training program. Feel free to browse this website for more details regarding research and clinical training opportunities available in our Division.

Richard B. Kim, MD, FRCPC, Division Chair.


News
June 4, 2010:
At the recent Canadian Society of Pharmacology & Therapeutics Annual Meeting (June2-4) in Toronto, Marianne DeGorter (Supervisor: Dr. Richard Kim) received the Best Trainee Oral Presentation Award and Michael Knauer (Supervisor: Dr. Rommel Tirona) received the Best Trainee Poster Presentation Award. Congratulations to both!
May 25, 2010:
Dr. Richard B. Kim, has been awarded a Cancer Care Ontario (CCO) Research Chair (Level 1) in Experimental Therapeutics .
He will receive $200,000/yr for 5 years with an opportunity to renew for an additional 3 years. CCO Chairs are awarded based on the excellence of the candidate and strategic alignment with one of the four CCO research theme areas. This award will facilitate his research in the areas of personalized anticancer therapy and experimental therapeutics.